Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017, Article ID 4691325, 3 pages
https://doi.org/10.1155/2017/4691325
Case Report

Life-Threatening Hemopericardium Associated with Rivaroxaban

1Department of Medicine, Reading Health System, West Reading, PA 19611, USA
2Tribhuvan University, Maharajgunj Medical Campus, Kathmandu, Nepal
3Universal College of Medical Sciences, Tribhuvan University, Bhairahawa, Nepal

Correspondence should be addressed to Sijan Basnet; moc.liamg@tensabnajis

Received 18 February 2017; Revised 21 March 2017; Accepted 3 April 2017; Published 5 April 2017

Academic Editor: Kjell Nikus

Copyright © 2017 Sijan Basnet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Rivaroxaban is a novel oral anticoagulant used in the treatment of venous thromboembolism. The use of this medication has expanded over the recent years with resultant expansion of side effect profile. We present a case of a 56-year-old female who presented with shortness of breath and chest pain 12 weeks after starting rivaroxaban for left upper extremity deep vein thrombosis. She was later diagnosed with spontaneous hemopericardium requiring pericardial fluid drainage. Rarer side effects like this will be encountered more often with the increasing use of novel oral anticoagulants. The clinicians should be cognizant of this entity among patients with shortness of breath and chest pain for timely diagnosis and intervention.